Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: A retrospective study in a single comprehensive European cancer institution

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  De Mello, Ramon Andrade ^a,b,c   Gerós, Sandra ^a,d   Alves, Marcos Pantarotto ^a   Moreira, Filipa ^c   Avezedo, Isabel ^a   Dinis, José ^a  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF ALGARVE   (Portugal)

^c University of Porto   (Portugal)

^d CENTRO HOSPITALAR DE VILA NOVA DE GAIA ESPINHO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; FLUOROURACIL; PLATINUM DERIVATIVE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PLATINUM;

ABSENCE OF SIDE EFFECTS; ADULT; ADVANCED CANCER; AGED; ALCOHOL CONSUMPTION; ANEMIA; ARTICLE; CANCER CONTROL; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CONTINUOUS INFUSION; DRUG CHOICE; DRUG EFFICACY; DRUG PREFERENCE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; FEVER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOMAGNESEMIA; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTATIC SQUAMOUS CELL CANCER OF HEAD AND NECK; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; RASH; RETROSPECTIVE STUDY; RISK FACTOR; SEPSIS; SMOKING; THROMBOCYTE COUNT; TUMOR LOCALIZATION; UNSPECIFIED SIDE EFFECT; VOMITING; CANCER GRADING; CARCINOMA, SQUAMOUS CELL; DISEASE FREE SURVIVAL; EUROPE; HEAD AND NECK NEOPLASMS; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; EUROPE; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PLATINUM; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84895514420     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0086697     Document Type: Article

References (39)

1. Jemal A, Bray F, Center M, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Massa E, Dessì M, Gaspardini G, Saba F, Cherchi V, et al. (2010) Phase II study of vinorelbine/cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck progressing after at least two chemotherapy regimens. Oral Oncol 46: 818-821.
3. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, et al. (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359: 1116-1127.
4. Gregoire V, Lefebvre J-L, Licitra L, Felip E (2010) Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21: v184-v186.
5. Haddad R, Tishler RB, Norris CM, Mahadevan A, Busse P, et al. (2003) Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment. Oncologist 8: 35-44. (Pubitemid 36232354)
6. Goodwin WJ (2000) Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means? Laryngoscope 110: 1-18.
7. Ho AS, Kraus DH, Ganly I, Lee NY, Shah JP, et al. (2013) Decision making in the management of recurrent head and neck cancer. Head Neck.
8. Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, et al. (2005) Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 23: 5578-5587.
9. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA (2005) Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23: 8646-8654. (Pubitemid 46211507)
10. Hitt R, Irigoyen A, Cortes-Funes H, Grau JJ, Garcia Saenz J, et al. (2012) Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol 23: 1016-1022.
11. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, et al. (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357: 1695-1704. (Pubitemid 350005151)
12. Clark JI, Greene JB, Clark AL, Dalal JS, Hofmeister CC (2013) Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer. Med Oncol 30: 1-6.
13. Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortés-Funes H, et al. (2005) Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 23: 5568-5577.
14. De Oliveira MG, Ramalho LMP, Gaião L, Pozza DH, De Mello RA (2012) Retinoblastoma and p53 protein expression in pre-malignant oral lesions and oral squamous cell carcinoma. Mol Med Rep 6: 163-166.
15. De Mello RA, Araújo A (2012) Epidermal growth factor receptor mutation frequency and non-small cell lung cancer management: implication for treatment choices. Clinics 67: 1349-1349.
16. Mesia R, Rivera F, Kawecki A, Rottey S, Hitt R, et al. (2010) Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 21: 1967-1973.
17. Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, et al. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247.
18. Brand TM, Iida M, Luthar N, Starr MM, Huppert EJ, et al. (2013) Nuclear EGFR as a molecular target in cancer. Radiother Oncol 13: S0167-8140.
19. Burtness B, Bauman JE, Galloway T (2013) Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition. Lancet Oncol 14: e302-e309.
20. Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, et al. (2009) Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 10: 247-257.
21. Zhou C, Wu Y-L, Chen G, Feng J, Liu X-Q, et al. (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12: 735-742.
22. de Mello RA, Ferreira M, Costa S, Costa BM, Pires FS, et al. (2012) Association between EGF+ 61 genetic polymorphisms and non-small cell lung cancer increased risk in a Portuguese population: a case-control study. Tumor Biol 33: 1341-1348.
23. de Mello RA, Marques DS, Medeiros R, Araújo AM (2011) Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies. World J Clin Oncol 2: 367.
24. Yoshino T, Hasegawa Y, Takahashi S, Monden N, Homma A, et al. (2013) Platinum-based Chemotherapy Plus Cetuximab for the First-line Treatment of Japanese Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Results of a Phase II Trial. Jpn J Clin Oncol 43: 524-531.
25. Cohen EE (2006) Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 24: 2659-2665.
26. Shahbazi M, Pravica V, Nasreen N, Fakhoury H, Fryer AA, et al. (2002) Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 359: 397-401. (Pubitemid 34158948)
27. Costa BM, Ferreira P, Costa S, Canedo P, Oliveira P, et al. (2007) Association between functional EGF+ 61 polymorphism and glioma risk. Clin Cancer Res 13: 2621-2626. (Pubitemid 46788028)
28. Araújo AP, Costa BM, Pinto-Correia AL, Fragoso M, Ferreira P, et al. (2011) Association between EGF+ 61A/G polymorphism and gastric cancer in Caucasians. World J Gastroenterol 17: 488.
29. Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, et al. (2010) Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: Results of the randomized multicenter phase III trial BMS099. J Clin Oncol 28: 911-917.
30. Flowers CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, et al. (2013) Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 31: 794-810.
31. Wood AJ, Pizzo PA (1993) Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 328: 1323-1332.
32. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, et al. (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52: e56-e93.
33. Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, et al. (2011) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol-EASE. J Clin Oncol 29: 1495-1501.
34. Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358: 2482-2494.
35. Celio L, Ricchini F, Braud F (2013) Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting. Patient Prefer Adherence 7: 391-400.
36. Barroso S, Damasceno M, Dinis J, Gervasio H, Da Luz R, et al. (2008) Guidelines for prevention of febrile neutropenia]. Acta Med Port 21: 7-19.
37. Cortinovis D, Beretta G, Piazza E, Luchena G, Aglione S, et al. (2012) Chemotherapy-induced anemia and oncologist perception on treatment: results of a web-based survey. Tumori 99: 45-50.
38. Link H, Schmitz S (2013) Treatment of Cancer-Associated Anaemia: Results from a Two-Day Cross-Sectional Survey in Germany. Onkologie 36: 266-272.
39. Argiris A, Kotsakis AP, Hoang T, Worden FP, Savvides P, et al. (2012) Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 24: 220-225.